Tirbanibulin
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alara Ece Dagsali, M.D.
Disclaimer
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
Overview
Tirbanibulin is a non-ATP competitive Src kinase inhibitor and tubulin polymerization inhibitor. that is FDA approved for the treatment of of actinic keratosis on the face or scalp. Common adverse reactions include *Application site pruritus
- Application site paina.
Adult Indications and Dosage
FDA-Labeled Indications and Dosage (Adult)
KLISYRI is indicated for the topical field treatment of actinic keratosis on the face or scalp. For topical use only; not for oral or ophthalmic use.
Apply KLISYRI evenly to cover up to 100 cm2 treatment field on the face or balding scalp once daily for 5 consecutive days using 1 unit-dose packet per application.
Wash hands immediately with soap and water after application.
Avoid washing and touching the treated area for approximately 8 hours after application of KLISYRI. Following this time, the area may be washed with a mild soap.
Avoid transfer of KLISYRI to the periocular area Avoid application near and around the mouth and lips.
Off-Label Use and Dosage (Adult)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Tirbanibulin in adult patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Tirbanibulin in adult patients.
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
There is limited information regarding Tirbanibulin FDA-Labeled Indications and Dosage (Pediatric) in the drug label.
Off-Label Use and Dosage (Pediatric)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Tirbanibulin in pediatric patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Tirbanibulin in pediatric patients.
Contraindications
None
Warnings
Ophthalmic Adverse Reactions: KLISYRI may cause eye irritation.
Avoid transfer of the drug into the eyes and to the periocular area during and after application. Wash hands immediately after application. If accidental exposure occurs, instruct patient to flush eyes with water and seek medical care as soon as possible.
Local Skin Reactions: Local skin reactions, including severe reactions (erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation and erosion/ulceration) in the treated area can occur after topical application of KLISYRI. Occlusion after topical application of KLISYRI is more likely to result in irritation. Avoid use until skin is healed from any previous drug, procedure, or surgical treatment.
Adverse Reactions
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
Two double-blind, vehicle-controlled clinical trials were conducted in 702 adult subjects with actinic keratosis on the face or scalp. Subjects were randomized 1:1 to KLISYRI or vehicle. Subjects enrolled in the trials had 4 to 8 clinically typical, visible, and discrete AK lesions in a contiguous area of 25 cm2 on the face or scalp. Subjects’ average age was 70 years (range 45 to 96 years) and they were predominantly White (99%), male (87%), with Fitzpatrick skin types I or II (72%) and actinic keratosis on the face (68%) or scalp (32%). Treatment groups were comparable across all demographics and baseline characteristics, including AK lesion count and distribution on the face or scalp.
In the controlled trials, local skin reactions (LSRs) were collected independent of adverse events. Local skin reactions including erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, erosions/ulcerations were assessed by the investigators using a grading scale of 0 = absent, 1 = mild (slightly, barely perceptible), 2 = moderate (distinct presence), and 3 = severe (marked, intense).
Postmarketing Experience
There is limited information regarding Tirbanibulin Postmarketing Experience in the drug label.
Drug Interactions
There is limited information regarding Tirbanibulin Drug Interactions in the drug label.
Use in Specific Populations
Pregnancy
Pregnancy Category (FDA):
There is no FDA guidance on usage of Tirbanibulin in women who are pregnant.
Pregnancy Category (AUS):
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Tirbanibulin in women who are pregnant.
Labor and Delivery
There are no available data with KLISYRI use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes.
In animal reproduction studies, oral administration of tirbanibulin to pregnant rats during the period of organogenesis resulted in an increased incidence of fetal deaths and malformations at a systemic exposure that was at least 19 times the exposure associated with the maximum recommended human dose (MRHD). Oral administration of tirbanibulin to pregnant rabbits during the period of organogenesis resulted in reduced mean fetal weight and size at a systemic exposure that was 41 times the exposure associated with the MRHD. The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.
Animal Data Tirbanibulin induced fetal deaths and external, visceral, and skeletal malformations when administered orally to pregnant rats during the period of organogenesis at doses greater than or equal to 1.25 mg/kg/day, which resulted in systemic exposures at least 19 times the exposure associated with the MRHD on an Area Under the Curve (AUC) comparison basis. Tirbanibulin had no apparent effects on fetal development in rats at a dose of 0.5 mg/kg/day, which resulted in systemic exposures 5 times the exposure associated with the MRHD.
Tirbanibulin reduced mean fetal weight and size (crown-rump length) when administered orally to pregnant rabbits during the period of organogenesis at a dose of 3 mg/kg/day, which resulted in a systemic exposure 41 times the exposure associated with the MRHD on an AUC comparison basis. Tirbanibulin had no apparent effects on fetal development in rabbits at a dose of 1 mg/kg/day, which resulted in systemic exposures 14 times the exposure associated with the MRHD.
Tirbanibulin was assessed for effects on peri- and post-natal development of rats in a study that involved oral administration to pregnant rats during the period of organogenesis through lactation at dosages up to 1.25 mg/kg/day. These dosages resulted in systemic exposures up to 19 times the exposure associated with the MRHD on an AUC comparison basis. No adverse effects on maternal function or developmental, neurobehavioral, or reproductive performance of offspring were observed.
Nursing Mothers
There are no data on lactational transfer of KLISYRI to human or animal milk. The effects of KLISYRI on the breastfed infant, or its effects on milk production, are unknown.
The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for KLISYRI and any potential adverse effects on the breastfed child from tirbanibulin or from the underlying maternal condition.
Pediatric Use
The safety and effectiveness of KLISYRI for actinic keratosis in subjects less than 18 years of age have not been established. Actinic keratosis is not a condition generally seen within the pediatric population.
Geriatic Use
Of the 353 subjects with AK treated with KLISYRI in the 2 controlled Phase 3 trials, 246 (70%) were 65 years of age or older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.
Gender
There is no FDA guidance on the use of Tirbanibulin with respect to specific gender populations.
Race
There is no FDA guidance on the use of Tirbanibulin with respect to specific racial populations.
Renal Impairment
There is no FDA guidance on the use of Tirbanibulin in patients with renal impairment.
Hepatic Impairment
There is no FDA guidance on the use of Tirbanibulin in patients with hepatic impairment.
Females of Reproductive Potential and Males
There is no FDA guidance on the use of Tirbanibulin in women of reproductive potentials and males.
Immunocompromised Patients
There is no FDA guidance one the use of Tirbanibulin in patients who are immunocompromised.
Administration and Monitoring
Administration
Apply KLISYRI evenly to cover up to 100 cm2 treatment field on the face or balding scalp once daily for 5 consecutive days using 1 unit-dose packet per application.
Wash hands immediately with soap and water after application.
Avoid washing and touching the treated area for approximately 8 hours after application of KLISYRI. Following this time, the area may be washed with a mild soap.
Avoid transfer of KLISYRI to the periocular area Avoid application near and around the mouth and lips.
Monitoring
There is limited information regarding Tirbanibulin Monitoring in the drug label.
IV Compatibility
There is limited information regarding the compatibility of Tirbanibulin and IV administrations.
Overdosage
There is limited information regarding Tirbanibulin overdosage. If you suspect drug poisoning or overdose, please contact the National Poison Help hotline (1-800-222-1222) immediately.
Pharmacology
There is limited information regarding Tirbanibulin Pharmacology in the drug label.
Mechanism of Action
Tirbanibulin is a microtubule inhibitor. The mechanism of action of KLISYRI for the topical treatment of actinic keratosis is unknown
Structure
There is limited information regarding Tirbanibulin Structure in the drug label.
Pharmacodynamics
The pharmacodynamics of tirbanibulin in the treatment of actinic keratosis is unknown.
Pharmacokinetics
Absorption: Following topical treatment of a mean daily dose of 348 mg (range: 224 to 435 mg) of KLISYRI to a 100 cm2 contiguous area of the face or balding scalp, once daily for 5 consecutive days. On Day 5, systemic exposure to tirbanibulin had a mean±SD maximum plasma concentration (Cmax) of 1.32±0.74 ng/mL and 0.71±0.31 ng/mL, and a mean±SD area under the plasma concentration from time zero to 24 hours (AUC24) of 19.6±8.1 h∗ng/mL and 11.7±4.4 h∗ng/mL, in subjects who received the face and scalp topical treatment, respectively. The median time to reach Cmax (Tmax) was ~6 hours.
Distribution: Plasma protein binding of tirbanibulin is 88% and is independent of concentrations in the range of 0.01 to 10 µg/mL.
Elimination: Metabolism:
Following topical treatment with KLISYRI to adult subjects with actinic keratosis, the plasma concentrations of KX2-5036, KX2-5163, and KX2-5180, three pharmacologically inactive metabolites, were detectable with the highest plasma concentrations of 0.36 ng/mL, 0.42 ng/mL, and 1.70 ng/mL, respectively.
The in vitro study indicated that incubation of 1 or 10 µM tirbanibulin with human hepatocytes generated KX2-5036, KX2-5162 and other unidentified metabolites.
In vitro, tirbanibulin is mainly metabolized by CYP3A4, and to a lesser extent, CYP2C8.
Excretion: Excretion of tirbanibulin has not been fully characterized in humans.
Drug Interactions Clinical Studies: No clinical studies evaluating the drug interaction potential of KLISYRI have been conducted.
In Vitro Studies CYP Enzymes: Tirbanibulin and the metabolite KX2-5036 directly or time-dependently inhibited CYP 1A2, 2B6, 2C8, 2C9, 2C19, 2D6, or 3A4 with an IC50 value of >17 µM. Tirbanibulin up to 1 µM (431.5 ng/mL) and the metabolite KX2-5036 up to 3 µM (1024 ng/mL) did not induce CYP 1A2, 2B6, or 3A4. The metabolite KX2-5180 was neither an inhibitor of CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6 or 3A4 with an IC50 value of > 225 nM (85 ng/mL) nor an inducer of CYP1A2, 2B6, and 3A4 at a concentration of 225 nM (85 ng/mL). These findings suggest that KLISYRI has no clinically meaningful effect on the PK of drugs metabolized by CYP 1A2, 2B6, 2C8, 2C9, 2C19, 2D6, or 3A4.
Drug Transporters: Neither tirbanibulin nor the metabolite KX2-5036 was a substrate of MDR1, BCRP, BSEP, MRP2, MATE1, MATE2-K, OAT1, OAT3, OATP1B1, OATP1B3, OCT1 or OCT2. The metabolite KX2-5180 was a substrate of BCRP, but not a substrate for other transporters. Tirbanibulin and the metabolites of KX2-5036 and KX2-5180 inhibited MDR1, BCRP, MRP2, BSEP, MATE1, MATE2-K, OAT1, OTA3, OATP1B1, OATP1B3, OCT1 and/or OCT2 with an IC5050 value of >1 µM. The results suggest that KLISYRI has no clinically meaningful effect on the PK of drugs mediated by MDR1, BCRP, MRP2, BSEP, MATE1, MATE2-K, OAT1, OTA3, OATP1B1, OATP1B3, OCT1 and OCT2.
Nonclinical Toxicology
No studies have been performed to evaluate the potential of tirbanibulin to induce carcinogenesis.
Tirbanibulin was negative in an in vitro bacterial reverse mutation (Ames) assay. Tirbanibulin was positive in an in vitro chromosomal aberration assay with Chinese hamster ovary (CHO) cells, an in vitro mouse lymphoma assay with L5178/TK+/- cells, and an in vivo micronucleus assay in rats.
Tirbanibulin was assessed for effects on fertility or reproductive function in rats. Reproductive performance of rats was unaffected by oral doses of tirbanibulin up to 4 mg/kg/day (24 times the MRHD on an AUC comparison basis) in males and 1 mg/kg/day (15 times the MRHD on an AUC comparison basis) in females. However, oral administration of 4 mg/kg/day of tirbanibulin to male rats adversely affected spermatogenesis, including reduced sperm count and motility, and increased observations of morphologically abnormal sperm. No effects on sperm were observed in males treated at 2 mg/kg/day (12 times the MRHD on an AUC comparison basis).
Clinical Studies
Actinic Keratosis of the Face or Scalp Two double-blind, vehicle-controlled clinical trials (NCT03285477 and NCT03285490) were conducted with 702 adult subjects with actinic keratosis on the face or scalp. Subjects were randomized 1:1 to KLISYRI or vehicle. Subjects enrolled had 4 to 8 clinically typical, visible, and discrete AK lesions in a contiguous area of 25 cm2 on the face or scalp. Subjects had an average age of 70 years (range 45 to 96 years), were predominantly White (99%), male (87%), with Fitzpatrick skin types I or II (72%) and actinic keratosis on the face (68%) or scalp (32%). Treatment groups were comparable across all demographics and baseline characteristics, including AK lesion count and distribution on the face or scalp.
Subjects received 5 consecutive days of once daily treatment with either KLISYRI (353) or vehicle control (349) to the treatment field. Subjects with complete (100%) clearance of AK lesions in the treatment area at Day 57 returned to the clinic for recurrence assessment every 3 months for a total of 12 months post-Day 57.
The primary efficacy endpoint was complete (100%) clearance of AK lesions in the treatment area, defined as the proportion of subjects at Day 57 with no clinically visible AK lesions in the treatment area and the secondary endpoint was partial (≥75%) clearance of AK lesions in the treatment area. Results from both trials are presented below.
How Supplied
KLISYRI is a white to off-white ointment and is supplied in unit-dose packets containing either 250 mg or 350 mg of tirbanibulin ointment 1%. Discard each unit-dose packet after use.
NDC 16110-391-05 (5 unit-dose packets each containing 250 mg of ointment) NDC 16110-391-55 (5 unit-dose packets each containing 350 mg of ointment)
Storage
Store at 20°C-25°C (68°F-77°F), excursions permitted to 15°C-30°C (59°F-86°F) [see USP Controlled Room Temperature]. Do not refrigerate or freeze.
Images
Drug Images
{{#ask: Page Name::Tirbanibulin |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}
Package and Label Display Panel
{{#ask: Label Page::Tirbanibulin |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}
Patient Counseling Information
Ophthalmic Adverse Reactions Advise patients that KLISYRI is not for ophthalmic use. Advise patients to avoid application around the eyes, and transfer of the drug into the eyes and to the periocular area. If accidental exposure occurs, advise patients to flush eyes with water and seek medical care
Local Skin Reactions: Inform patients that treatment with KLISYRI may lead to local skin reactions
Important Administration Instructions: Advise patients that KLISYRI is for topical use only. Advise patients to avoid application near and around the eyes, mouth and lips.
Instruct patients to:
- Wash hands well after applying KLISYRI to avoid transfer of the drug into the eyes and to the periocular area after application.
- Avoid washing and touching the treated area for 8 hours after treatment. Following this time, patients may wash the area with a mild soap and water
- Avoid inadvertent transfer of KLISYRI to other areas, or to another person.
Precautions with Alcohol
Alcohol-Tirbanibulin interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
Brand Names
Klisyri
Look-Alike Drug Names
There is limited information regarding Tirbanibulin Look-Alike Drug Names in the drug label.
Drug Shortage Status
Price
References
The contents of this FDA label are provided by the National Library of Medicine.